natgillin/translations-raw huggingface dataset:
300 mg twice daily n=282 (%)
300 mg dvakrat dnevno n=282 (%)
300 mg weekly x 1
300 mg tedensko x 1
300 mg zidovudine
300 mg zidovudina
300 mg) and proton-pump inhibitors has been reported to increase methotrexate levels in some patients.
300 mg) in zaviralcev protonske črpalke so pri posameznih bolnikih poročali o zvišanju vrednosti metotreksata.
300 mg/960 mg, 600 mg/1920 mg and 900 mg/2880 mg).
600 mg/1 920 mg in 900 mg/2880 mg).
300 mg/ritonavir 100 mg once
300 mg/ritonavirjem 100 mg
300 mg/ritonavir 100 mg once daily in
300 mg/ritonavirjem 100 mg
300 mg/ritonavir 100 mg once daily)
300 mg/ritonavir 100 mg enkrat na dan)
300 micrograms/24 hours
300 mikrogramov/24 ur
300 micrograms/m2 intramuscularly
300 mikrogramov/m2 intramsukularno
300 micrograms/m2 intramuscularly (mcg/kg) (ml)
300 mikrogramov/m2 intramsukularno (mikrogramov/kg) (ml)
300 ml [bottle label only]
300 ml [samo na nalepki na steklenici]
300 ml amber glass bottle (type III) with a white child resistant closure (polypropylene) in a box also containing a 10 ml graduated oral dosing syringe (polypropylene, polyethylene) and an adaptor for the syringe (polyethylene).
300 ml steklenica (tip III) jantarne barve z belo zaporko, varno za otroke (polipropilen) v škatli, ki vsebuje še 10 ml graduirano brizgo za peroralno odmerjanje (polipropilen, polietilen) in adapter za brizgo (polietilen).
300 ml oral solution
300 ml peroralne raztopine.
300 tablets
300 tablet
300 to 500 mg per day
300 do 500 mg na dan (enkrat na dan ali dva deljena odmerka).
300 to <500 cells/L
300 do < 500 celic/l
300 units/ml
300 enot/ml
300/100 mg once daily
300/100 mg enkrat na
300/100 mg QD
300/100 mg 1-krat na dan
3000
AUC 0–24 ur
3000 IU (octocog alfa) (600 IU/mL after reconstitution).
3000 a.e. (októkóg alfa) (600 a.e./ml eftir blöndun).
3000 IU moroctocog alfa for single IV use
3.000 i.e. moroktokoga alfa za enkratno i.v. uporabo
3000 IU octocog alfa
3000 i.e. oktokoga alfa
3000 IU octocog alfa (600 IU/ml after reconstitution).
3000 i.e. oktokoga alfa (po rekonstituciji 600 i.e./ml).
3000 IU/0.3 ml
3000 i.e. /
3000 IU/0.5 ml
3000 i.e./0,5 ml
3000 IU/0.9 ml
3000 i.e./0,9 ml
3000 mg/day
3.000 mg/dan
30000 IU/0.75 ml
30000 i.e./0,75 ml
30000 IU/1.0 ml
30.000 i.e./1,0
30000 Nîmes France
30000 Nîmes Francija
300mg (6 sachetsa)
300 mg (6 vrečica)
3014 Bern SWITZERLAND
3014 Bern ŠVICA
302mL p<0.001 (178, 426)
302 ml p < 0,001 (178, 426)
303 (272, 333)
Parameter
305 (80.5)a
305 (80,5) a
305 74770 Opava-Komarov Czech Republic
305 74770 Opava-Komarov Češka
305, 74770 Opava-Komarov, Czech Republic
305 74770 Opava-Komarov Češka
307 (70.9)a
307 (70,9) a
309 patients had a count ≤ 25,000/μl during the study.
Izmed 309 bolnikov, ki so imeli začetno število trombocitov > 75.000/μl, jih je samo 14 % imelo med preskušanjem število trombocitov ≤ 25.000/μl.
309.2
(SD)
30th June 2018
30. junij 2018
30th June, 2019
30. junij 2019
30th September 2015
31. decembra 2015
30th September 2017
izvedene v študiji CA209-066.
30x1 capsule (unit dose) +
30x1 kapsula (enkratni
30x1 film-coated tablets
30x1 filmsko obložena tableta
30x1 film-coated tablets 50 film-coated tablets 50x1 film-coated tablets 56 film-coated tablets
50 filmsko obloženih tablet 50x1 filmsko obloženih tablet 56 filmsko obloženih tablet
30x1 film-coated tablets.
30 x 1 filmsko obloženih tableta
30x1 film-coated tablets.
30 x1 filmsko obloženih tableta
30x1 tablets (unit dose)
30 x 1 tableta (enkratni odmerek)
30x1 tablets (unit dose)
30 x 1 tableta (odmerek)
30x1, 50x1, 90x1 and 100x1 tablet in all-aluminium perforated unit-dose blisters.
30 x 1, 50 x 1, 90 x 1 in 100 x 1 tableto v aluminijastih perforiranih pretisnih omotih za enkratni odmerek
30–39 3.0 mg* zoledronic acid
30–39 3,0 mg* zoledronske kisline
30–60 Every 24 hours, at least 1 day, until healing is achieved.
30–60 Na vsakih 24 h, najmanj 1 dan, dokler se ne začne celjenje.
30–60 Repeat infusion every 12 to 24 hours for 3 to 4 days or more until pain and acute disability are resolved.
30–60 Infuzije ponavljajte na vsakih 12 do 24 ur 3 do 4 dni ali več, dokler ne mineta bolečina in akutna onesposobljenost.
31 60 minutes, half the dose must be taken again.
31–60 minut po uporabi, je treba ponovno vzeti polovico odmerka.
31 December 2021.
31. decembra 2021.
31 hours
31 ur
31 IU/kg (21;
31 a.e./kg
31 July 2015
31. julij 2015
31 March 2025
OZNAČEVANJE
31% (13) (p=0.10b
31 % (13)
31% (19.9, 43.4) P < 0.001b
31 % (19,9, 43,4) p < 0,001b
31% (N=129) had received 1 prior line of therapy (EGFR-TKI treatment only), 69% (N=282) had received 2 or more prior lines.
31 % (n = 129) je prejelo 1 predhodno linijo zdravljenja (le zdravljenje z EGFR-TKI) in 69 % (n = 282) jih je prejelo 2 ali več predhodnih linij.
31% had localised prostate cancer
31 % lokaliziranega raka prostate,
31%† (n = 220)
31 %† (n = 220)
31-546 Krakow Poland
Krakow 31-546 Poljska
31-546 Kraków Poland
31-546 Kraków, Poljska
31-546 Kraków Poland
31-546 KrakówPoljska
31-546, Krakow,
31-546, Krakow Poljska
31-60 minutes, half the dose must be taken again.
31–60 minut po uporabi, je treba ponovno vzeti polovico odmerka.
31.25x109 bacteria* of each of the following V. cholerae O1 strains: Inaba classical biotype (heat inactivated), Inaba El Tor biotype (formalin inactivated), Ogawa classical biotype (heat inactivated), Ogawa classical biotype (formalin inactivated).
31,25 x 109 bakterij* vsake od naslednjih sevov bakterije V. cholerae O1: klasični biotip Inaba (inaktiviran s toploto), biotip Inaba El Tor (inaktiviran s formalinom), klasični biotip Ogawa (inaktiviran s toploto), klasični biotip Ogawa (inaktiviran s formalinom).
310
DOE
31028 Gronau/Leine Germany
31028 Gronau/Leine Nemčija
31057 Toulouse Cedex FRANCE
4, chemin du Calquet 31057 Toulouse Cedex FRANCIJA
312 IU/1 ml
312 i.e./1 mL
312 IU/ml
312 i.e./ml
316 177 148 127 114 104 94 46 8 0
316 177 148 127 114 104 94 46 8 0 ipilimumab
316,000 cells/cm²
316.000 celic/cm2
319 Pinner Road
Sage House 319 Pinner road
319 subjects with AK were treated with up to 2 sachets once daily of Imiquimod 3.75% cream, or a matching vehicle cream for two 2-week treatment cycles separated by a 2-week no-treatment cycle.
319 preiskovancev z AK je bilo zdravljenih z do 2 vrečicama imikvimod 3,75 % kreme na dan ali ujemajočo se kremo z vehiklom v dveh dvotedenskih ciklusih zdravljenja, med katerima je bil dvotedenski odmor brez zdravljenja.
31st December 2017
31. december 2017
31st March 2017
30. september 2015
31st October 2016
31. oktober 2016
32 cases were considered to have scarce information regarding underlying history and concomitant drugs, at least five of them have compatible chronology; but a causal association cannot be excluded in these cases.
V 32 primerih je bilo ocenjeno, da je informacij o osnovni anamnezi in sočasnih zdravilih zelo malo, vsaj 5 od teh pa je imelo združljivo kronologijo; vzročne povezanosti v teh primerih ni mogoče izključiti.
32 cells/mm3 in the PI+RTV+FTC/TDF-treated patients.
32 celic/mm3 za bolnike, zdravljene z PI+RTV+FTC/TDF.
32 D units
32 enot D
32 IU/kg (22;
32 a.e./kg
32 IU/kg (22;
32 i.e./kg
32 ml bottle
32 ml steklenička
32 tablets
32 tablet
32 weeks
32 tednov
32 weeksa (n/N)
32-tedenskega obdobjaa (n/N)
32 x 1 modified-release tablets
32 x 1 tableta s prirejenim sproščanjem
32 x 1 tablets (unit dose)
32 x 1 tableta (za enkratni odmerek)
32% (8-56)
Citogenetski odzivc (%)
32% lower, respectively, as compared with postpartum; during the third trimester of pregnancy, total darunavir Cmax, AUC12h and Cmin values were 31%, 35% and 50% lower, respectively, as compared with postpartum.
Med tretjim trimesečjem nosečnosti pa so bile vrednosti celokupnega darunavirja Cmax, AUC12h in Cmin za 31%, 35% oziroma 50% manjše kot v obdobju po porodu
32% of patients in the Abraxane/gemcitabine arm compared with 15% of patients in the gemcitabine arm received 6 or more months of treatment.
V skupini z zdravilom Abraxane/gemcitabinom je 32 % bolnikov prejelo 6 ali več mesecev zdravljenja, v skupini z gemcitabinom pa 15 %.
32.27 g
prašek: 32,27 g
32.5 to < 40
32.5 do < 40
32004 data.
3Podatki iz leta 2004.
326 cattle received Metacam given as an injection together with antibiotic therapy whilst 326 cattle received a dummy injection and antibiotic therapy.
326 živali je prejelo zdravilo Metacam v obliki injekcije skupaj z antibiotiki, medtem ko je drugih 326 živali prejelo injekcijo brez zdravilne učinkovine skupaj z antibiotiki.
327 patients undergoing hip fracture surgery treated for 3 weeks following an initial prophylaxis of 1 week
327 bolnikih po operaciji zaradi zloma kolka, ki so po začetni enotedenski profilaksi prejemali zdravilo še 3 tedne.
327 patients who had been treated with NRTIs but not with PIs or NNRTIs.
327 bolnikov, zdravljenih z NRTI, ne pa z ZP ali NNRTI.
329 333
Odzivni bolniki (%)
33 (26-NR)
33 (26-ND)
33 ml/50 ml vial
33 ml/50 ml viala
33 of these patients were provided with continued treatment with bosentan dispersible tablets at a dose of 4 mg/kg twice daily in the FUTURE 2 uncontrolled extension phase for a median overall treatment duration of 2.3 years (range: 0.2 to 5.0 years).
33 od teh bolnikov je nadaljevalo zdravljenje z disperzibilnimi tabletami bosentana v odmerku 4 mg/kg dvakrat dnevno v nenadzorovani podaljšani fazi študije FUTURE 2, kjer je bila skupno mediana trajanja zdravljenja znašalo 2,3 leta (razpon: 0,2 do 5,0 let).
33,140 vaccinated
33.140 cepljenih
33.0 months (95% CI; 28.9-37.1 months) for the Caelyx plus bortezomib combination therapy patients.
33,0 mesecev (95% IZ; 28,9-37,1 meseca).
33.3 mg/g prednisolone.
prednizolon 33,3 mg/g.
33.4 (18.1, NE)
33,4 (18,1; N.o.)
33.6 micrograms
33,6 mikrogramov
330 (76.4)a
330 (76,4) a
332 patients who received docetaxel in combination with prednisone or prednisolone (clinically important treatment related adverse events are presented).
332 bolnikih, ki so dobivali docetaksel v kombinaciji s prednizonom ali prednizolonom (predstavljeni so klinično pomembni, z zdravljenjem povezani, neţeleni učinki);
332 patients who received docetaxel in combination with prednisone or prednisolone (clinically important treatment related adverse events are presented).
332 bolnikih, ki so dobivali docetaksel v kombinaciji s prednizonom ali prednizolonom (predstavljeni so klinično pomembni, z zdravljenjem povezani, neželeni učinki);
332 patients who received docetaxel in combination with prednisone or prednisolone (clinically important treatment related adverse events are presented).
332 bolnikih, ki so prejemali docetaksel v kombinaciji s prednizonom ali prednizolonom (predstavljeni so klinično pomembni z zdravljenjem povezani neželeni učinki).
332 patients who received docetaxel in combination with prednisone or prednisolone (clinically important treatment related adverse events are presented).
332 bolnikih, ki so prejemali docetaksel v kombinaciji s prednizonom ali prednizolonom(predstavljeni so klinično pomembni z zdravljenjem povezani neželeni učinki).
333 IU/mL after reconstitution)
333 i.e./ml po rekonstituciji)
33428 Harsewinkel North Rhine-Westphalia Germany
33428 Harsewinkel North Rhine-Westphalia Nemčija
3350, talc (E553b), iron oxide yellow (E172), iron oxide red (E172) and iron oxide black (E172).
3350, smukec (E553b), rumeni železov oksid (E172), rdeči železov oksid (E172), črni železov oksid (E172).
33500 Libourne France
Francija
33565 Carbon-Blanc-Cedex France
33565 Carbon-Blanc-Cedex Francija
336 (85.9)a
336 (85,9) a
336 tablets
336 tablet
336.0 micrograms
336,0 mikrogramov
33790 Halle/Westfalen Germany
33790 Halle/Westfalen Nemčija
338 Euston Road London NW1 3BT United Kingdom
338 Euston Road London NW1 3BT Velika Britanija
338 Euston Road London NW1 3BT United Kingdom
Regent’s Place 338 Euston Road London NW1 3BT Velika Britanija
34 subjects (29 with HCV genotype 1a infection and 5 with HCV genotype 1b infection) were enrolled who had not received treatment for HCV infection after transplantation and had a METAVIR fibrosis score of F2 or less.
Vključenih je bilo 34 preiskovancev (29 z okužbo s HCV genotipa 1a in 5 z okužbo s HCV genotipa 1b), ki po presaditvi niso bili zdravljeni zaradi okužbe s HCV in so imeli oceno fibroze po METAVIR F2 ali manj.
34-41.4 kg
34-41,4 kg največji odmerek
34.5 to 38.1
34,5 do 38,1
34.6
vrednost p
340 mg cefovecin
340 mg cefovecina
340 mg cefovecin (as sodium salt)
340 mg cefovecina (v obliki natrijeve soli)
35 041 Marburg Germany
35 041 Marburg Nemčija
35 cm Rigid Tip
Togi nastavek dolžine 35 cm
35 coated tablets
35 obloženih tablet
35 g of mycophenolate mofetil in 110 g powder for oral suspension
35 g mofetilmikofenolata v 110 g praška za peroralno suspenzijo
35 kg < calves ≤ 45 kg: 8 ml of HALOCUR once a day during 7 consecutive days
35 kg < teleta ≤ 45 kg: 8 ml zdravila HALOCUR, 1-krat na dan, 7 zaporednih dni
35 kg < calves ≤ 45 kg: 8 ml of HALOCUR once a day for 7 consecutive days
35 kg < teleta ≤ 45 kg: 8 ml zdravila HALOCUR, 1-krat na dan, 7 zaporednih dni
35 mg (0.35 ml) twice daily
35 mg (0,35 ml) dvakrat na dan
35 mg (0.35 ml) twice daily
35 mg (0.35 ml) dvakrat na dan
35 mg for moderate hepatic impairment (from one 50 mg vial) at reduced volume
35 mg pri zmerni jetrni okvari (iz ene 50 ml viale) / zmanjšana prostornina infuzije
35 mg for moderate hepatic impairment (from one 50 mg vial) at reduced volume
35 mg pri zmerni jetrni okvari (iz ene viale po 50 mg)
35 mg for moderate hepatic impairment (from one 70 mg vial)
35 mg pri zmerni jetrni okvari (iz ene 70 mg viale)
35 orodispersible tablets
35 orodisperzibilnih tablet
35 tablets
28 tablet
35 tablets
35 tablet
35 tablets
56 tablet
35 tablets
EU/1/96/022/020
35 Units/kg) every other week for up to 84 months (7 years).
35 enot/kg) vsak drugi teden do 84 mesecev (7 let).
35 ± 4 days
35 ± 4 dni
35 g/1 mg once daily
35 g/1 mg enkrat na dan
35% (n = 51)
35 % (n = 51)
35% increase 1)
35-odstotno povečanje 1)
35) in the per-protocol analysis and by 23 % (95 % CI: 11, 34) in the intent-to-treat analysis.
12, 35) pri otrocih, ki so opravili vsa cepljenja skladno s protokolom cepljenja, in za 23 % (95-odstotni interval zaupanja: 11, 34) pri otrocih, ki so jih cepili.
35, 35 x 1, 50, 50 x 1, 56, 56 x 1, 60, 70, 70 x 1, 98 or 98 x1 film-coated tablets.
30 x 1, 35, 35 x 1, 50, 50 x 1, 56, 56 x 1, 60, 70, 70 x 1, 98 ali 98 x 1 filmsko obložena tableta.
35, 56, 70 (2 x 35 multipack) and 70 film-coated tablets.
30, 35, 56, 70 (2 paketa po 35tablet) in 70 filmsko obloženih tablet.
35, 89257 Illertissen Germany
35, 89257 Illertissen Nemčija
35.2 g Monensin sodium (equivalent to 32.4 g monensin).
35,2 g monenzin natrij (kar ustreza 32,4 g monenzina).
35.2-162 ng/mL (25th-75th percentile range).The dabigatran geometric mean trough concentration, measured at the end of the dosing interval (i.e.
Geometrična sredina najmanjše koncentracije dabigatrana, izmerjene ob koncu odmernega intervala (tj.
35.2-162 ng/mL (25th–75th percentile range).The dabigatran geometric mean trough concentration, measured at the end of the dosing interval (i.e.
Geometrična sredina najmanjše koncentracije dabigatrana, izmerjene ob koncu odmernega intervala (tj.
35.3 (32.2, NR)
35,3 (32,2, ND)
35.5 (19.3-NA)
35,5 (19,3–NP)
350 mg (4.4 ml) twice daily
350 mg (4,4 ml) dvakrat na dan
350 tablets
350 tablet
3500 IU
3500 i.e.
35039 Marburg Germany
35039 Marburg Nemčija
35041 Marburg GERMANY
35041 Marburg NEMČIJA
352 days (docetaxel alone).
352 dnevi (samo docetaksel).
354 (81.8)a
354 (81,8) a
3550–7100 U1
3550-7000 U1
357 (82.6)a
357 (82,6) a
357 patients from the placebo-controlled study entered a long-term extension study.
357 bolnikov iz placebo kontrolirane študije je bilo vključenih v dolgoročno podaljšano študijo.
36 (51.4%)
N=38
36 blisters (252 tablets)
36 pretisnih omotov (252 tablet)
36 IU/kg (21;
36 a.e./kg
36 months
mesecev
36 months (83% and 77%), 48 months (83% and 79%) and 60 months (83% and 79%) were consistent with the primary endpoint.
24 mesecih (80% oziroma 74%), 36 mesecih (83% in 77%), 48 mesecih (83% in 79%) ter 60 mesecih (83% in 79%) konsistentni s primarnim opazovanim dogodkom.
36 months after the 1st dose N=387
36 mesecev po prvem odmerku n=387
36 months after the 1st dose N=387
Dvojni odmerek n=10
36 to less than 75
36 do manj kot 75
36-month survival (%)
36-mesečno preživetje (%)
36.5 months versus 15.1 months in the R-CHOP group).
36,5 mesecev proti 15,1 meseca v skupini R-CHOP).
36.9 μg•h/ml, 10.0 ± 3.3 μg/ml and 3.6 ± 3.5 μg/ml, respectively after 300/75 mg/m2 twice daily with nevirapine (n=12).
300 mg/75 mg/m2, dvakrat na dan z nevirapinom (n=12) pa; 85,8 ± 36.9 μgh/ml, 10,0 ± 3,3 μg/ml in 3,6 ± 3,5 μg/ml.
360 (3 x 120) tablets
360 (3 x 120) tablet
360 (4 x 90 x 1) tablets
360 (4 x 90 x 1) tablet
360 (6x60) tablets (multipack)
360 (6x60) tablet (skupno pakiranje)
360 capsules
360 kapsul
360 hard capsules
360 trdih kapsul
360 micrograms PRE-FILLED SYRINGES LABEL
NALEPKA ZA NAPOLNJENO INJEKCIJSKO BRIZGO 360 mikrogramov
360 tablets
360 filmsko obloženih tablet
360 tablets
360 tablet
360 tablets (4 x 90 x 1)
360 (4 x 90 x 1) tablet
360 tablets: EU/1/09/579/006
360 tablet: EU/1/09/579/006
360 tablets: EU/1/09/579/012
360 tablet: EU/1/09/579/012
360 tablets: EU/1/09/579/018
360 tablet: EU/1/09/579/018
360 tablets: EU/1/09/580/006
360 tablet: EU/1/09/580/006
360 tablets: EU/1/09/580/012
360 tablet: EU/1/09/580/012
360 tablets: EU/1/09/580/018
360 tablet: EU/1/09/580/018
3600 mg/kg/day.
3.600 mg/kg/dan.
3600 mg/kg/day.
3600 mg/kg/dan.
3600 x Wt
0,84 – 1,16
361.8 mg (S)- methoprene, 480 mg amitraz
402 mg fipronil, 361,8 mg (S)-methopren, 480 mg amitraz
364 tablets (312
(PVC/alu)
36400 O Porriño Pontevedra, Spain
36400 O Porriño Pontevedra, Španija
36400 Porriño SPAIN
36400 Porriño ŠPANIJA
36mL p=0.405 (-48, 120)
(-48, 120)
37 (0.24)
n = 2.798
37 (10.2)
Padec
37 (37.8)
(SD)
37 cats received Metacam and 39 cats received carprofen (another NSAID) by subcutaneous (under the skin) injection immediately after induction of anaesthesia.
37 mačk je prejelo zdravilo Metacam, 39 pa karprofen (drugo nesteroidno protivnetno zdravilo) s podkožno injekcijo tik po uvedbi anestezije.
37 deaths occurred prior to a decision taken by the Data Monitoring Committee to down titrate subjects to a lower dosage, based on an observed mortality imbalance with increasing sildenafil doses.
37 smrti se je pojavilo pred odločitvijo Odbora za preverjanje podatkov (DMC – data monitoring committee), da se pri preiskovancih opravi titracija na manjši odmerek, kar je temeljilo na opaženem neravnovesju umrljivosti pri večjih odmerkih sildenafila.
37 GBq yttrium-90
37 GBq itrij-90
37 IU/kg (30;
37 a.e./kg
37.0%
N/A
37.5 mg hard capsules
37,5 mg trde kapsule
37.5 mg hard capsules Capsule content Mannitol (E421) Croscarmellose sodium Povidone (K-25) Magnesium stearate
vsebina kapsule manitol (E421) premreženi natrijev karmelozat povidon (K-25)
37.5% and 32.1% for 75 mg, 150 mg and 300 mg, respectively, compared to placebo 6.3%).
Podobno velja tudi za odziv ACR 50 (9,6%, 37,5% oziroma 32,1% pri odmerkih 75 mg, 150 mg oziroma 300 mg v primerjavi s 6,3% pri uporabi placeba).
37.5% vs 0%
37,5 % v prim. z 0
37/2010 indicates that no MRLs are required.
37/2010 določa, da navedba MRL ni potrebna.
37081 Göttingen Germany
37081 Göttingen Nemčija
3732 CN De Bilt The Netherlands
3732 CN De Bilt Nizozemska
374 102 600
Tel: +40 374 102 600
375 mg PREZISTA/50 mg ritonavir twice daily
375 mg PREZISTA/50 mg ritonavir a dvakrat na dan
375 mg tablet: macrogol, polysorbate 80, Blue #2/Indigo Carmine Aluminium Lake (E132)
375-miligramska tableta: makrogol, polisorbat 80, modro aluminijevo barvilo indigotin št.
375 mg/m2 body surface area [BSA], subsequent cycles at 500 mg/m2 BSA) in combination with either an oral placebo twice daily or with idelalisib 150 mg taken twice daily until disease progression or unacceptable toxicity.
500 mg/m2 BSA) v kombinaciji z bodisi peroralnim placebom dvakrat na dan ali z idelalizibom 150 mg dvakrat na dan do napredovanja bolezni ali nesprejemljive toksičnosti.
375 milligram PREZISTA + 50 milligram ritonavir twice a day
375 miligramov zdravila PREZISTA + 50 miligramov ritonavirja dvakrat na dan
37530 Pocé-sur-Cisse BELGIUM FRANCE
37530 Pocé-sur-Cisse BELGIJA FRANCIJA
378 meters and 326 meters respectively; fewer patients were Class I (1/277, 0.4 %) or IV (9/277, 3 %) at baseline.
326 metrov na 6-minutnem testu hoje ob začetku študije; manj bolnikov je bilo ob začetku študije v razredu I (1/277, 0,4 %) ali IV (9/277, 3 %).
37°C (e.g., water bath, using aseptic technique, or by warming vials in the hand): vials should be thawed within 10 minutes and must not be left at this temperature for longer than 10 minutes or until fully thawed.
37 °C (npr. vodna kopel, z aseptično tehniko ali segrevanje v dlani): viale se odtalijo v 10 minutah; pri tej temperaturi jih ne smete pustiti dlje kot 10 minut oz. dokler se popolnoma ne odtalijo.
37°C (e.g., water bath, using aseptic technique, or by warming vials in the hand): vials should be thawed within 10 minutes and must not be left at this temperature for longer than 10 minutes or until fully thawed.
37 °C (npr. vodna kopel, z aseptično tehniko ali segrevanje v dlani): viale se odtalijo v 10 minutah; pri tej temperaturi jih ne smete pustiti dlje kot 10 minut oziroma dokler se popolnoma ne odtalijo.
38 a
45 a
38 mm (1.5 inch) 22 gauge
38 mm, velikost 22
38% at least 1 Gd+ lesion at baseline 92% ≥9 T2 lesions baseline
38 % vsaj 1 z Gd+ vidno lezijo ob izhodišču 92 % ≥ 9 T2 lezij ob izhodišču
38.2 to 41.7
38,2 do 41,7
38.5 micrograms blinatumomab powder in a vial (type I glass) with a stopper (elastomeric rubber), seal (aluminium) and a flip off cap and
38,5 mikrogramov praška blinatumomaba v viali (steklo tipa I) z zamaškom (elastomerna guma), zaporo (aluminij) in snemno zaporko, in
38.6% for 75 mg, 150 mg and 300 mg, respectively, compared to placebo 8.0%).
Podobno velja tudi za odziv ACR 50 (27,7%, 31,8% oziroma 38,6% pri odmerkih 75 mg, 150 mg oziroma 300 mg v primerjavi z 8,0% pri uporabi placeba).
38.7 mg pyriproxifen, 3,175 mg permethrin
38.7 mg piriproksifen, 3175 mg permetrin
38.9%
Izidi
380
DOE
380 milligram (3.8 milliliter)
380 miligramov (3,8 mililitra)
385*
Vsi bolniki
386 (89.1)a
386 (89,1) a
389 Chiswick High Road London W4 4AL
Actelion Registration Ltd Chiswick Tower 13th Floor 389 Chiswick High Road London W4 4AL
39 (55.7%)
2 stopnji).
39 Hurley Street Cambridge
39 Hurley Street
39 IU/kg)
39 a.e./kg
39% (28.0, 51.2) P < 0.001b
39 % (28,0, 51,2) p < 0,001b
39% in placebo treated patients.
39 % bolnikov, zdravljenih s placebom.
39-2.10 Inactivated feline Chlamydophila felis (Cello strain): R.P. 1.69-3.50 Inactivated feline leukaemia virus (61E strain): R.P. 1.45-2.00.
39-2.10 Inaktivirana Chlamydophila felis (sev Cello): R.P. 1.69-3.50 Inaktiviran virus mačje leukemije (sev 61E): R.P. 1.45-2.00.
39.6 (p=0.0160)
39,6 (p = 0,0160)
391 days (Mayo regimen).
392 dni (kapecitabin) v primerjavi s 391 dnevi (shema Mayo).
39179 Barleben Germany
39179 Barleben Nemčija
3: cases of interstitial lung disease (predominantly interstitial pneumonia and eosinophilic pneumonia) have been reported from post-marketing experience with telmisartan
3 v obdobju po začetku trženja telmisartana so poročali o primerih intersticijske pljučne bolezni (pretežno intersticijske pljučnice in eozinofilne pljučnice)
3: For further description, please see sub-section”Description of selected adverse reactions”
3: Za podrobnejši opis glejte podpoglavje »Opis izbranih neželenih učinkov«
3: For further descriptions, please see sub-section “Description of selected adverse reactions”
3: Za podrobnejši opis glejte podpoglavje »Opis izbranih neželenih učinkov«
3: For further descriptions, please see sub-section”Description of selected adverse reactions”
3: Za podrobnejši opis glejte podpoglavje »Opis izbranih neželenih učinkov«
3: Needle guard activation clips
3: aktivacijska nastavka za varovalo za iglo
3adsorbed on aluminium hydroxide, hydrated (Al(OH)3) 0.5 milligrams Al3+ in total
3adsorbiran na hidratirani aluminijev hidroksid (Al(OH)3) 0,5 miligrama Al3+ v celoti
3adsorbed on aluminium hydroxide, hydrated (Al(OH)3) 0.5 milligrams Al3+ in total
3adsorbiran na hidratirani aluminijev hidroksid (Al(OH)3) 0,5 miligrama Al3+v celoti
3adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.225 milligrams Al).
3adsorbiran na amorfni aluminijev hidroksifosfat sulfat kot adjuvans (0,225 miligramov Al)